Regulus, Biogen Idec deal

Regulus partnered with Biogen Idec to identify microRNA biomarkers in blood from multiple sclerosis patients who received treatment with a Biogen Idec product. Regulus said it will use samples from patients treated in Biogen Idec clinical trials. Regulus will receive $2 million up front and will be eligible for undisclosed milestones. The partners simultaneously terminated a similar 2012 deal to identify biomarkers using blood from MS patients and healthy volunteers and said results from studies under that deal helped define the scope of the new deal. The partners could not be reached for details (see BioCentury, Aug. 15, 2012). ...